Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivabradine modified-release versus immediate-release in stable coronary artery disease
NL-OMON36887Phase 3Active, not recruiting
- Sponsor
- Servier
- Start
- Nov 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ivabradine in coronary arteriosclerosis and angina pectoris (2 arms), sponsored by Servier. Primary endpoint: Emergent adverse events over 6 months. Started Nov 2012; status: active, not recruiting.
02
Drugs
ivabradine
03
Conditions
coronary arteriosclerosisangina pectoris
Beyond the preview
Go deeper on NL-OMON36887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36887.